<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02178943</url>
  </required_header>
  <id_info>
    <org_study_id>SN-C-00004</org_study_id>
    <nct_id>NCT02178943</nct_id>
  </id_info>
  <brief_title>Utility of Donor-Derived Cell Free DNA in Association With Gene Expression Profiling</brief_title>
  <acronym>D-OAR</acronym>
  <official_title>Utility of Donor-Derived Cell-free DNA in Association With Gene-Expression Profiling (AlloMap®) in Heart Transplant Recipients (D-OAR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CareDx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CareDx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Plasma donor-derived cell-free DNA (dd-cfDNA) is measured as a % of the total plasma cfDNA in
      association with the measurement of AlloMap, a non-invasive gene expression test to aid in
      heart transplant management.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AlloMap Molecular Expression Testing is performed in a single laboratory, assessing the gene
      expression profile of RNA isolated from peripheral blood mononuclear cells (PBMC). Per FDA
      labeling, AlloMap Testing is &quot;intended to aid in the identification of heart transplant
      recipients with stable allograft function who have a low probability of moderate/severe acute
      cellular rejection (ACR) at the time of testing in conjunction with standard clinical
      assessment.&quot; AlloMap is the only non-invasive, blood test method recommended in the
      International Society for Heart and Lung Transplantation (ISHLT) guidelines for surveillance
      of heart transplant recipients for rejection. More than 52,000 commercial AlloMap tests from
      more than 12,000 patients have been reported by the XDx Reference Laboratory in Brisbane,
      California, which is certified under the Clinical Laboratory Improvement Amendment (CLIA) of
      1988 and accredited by the College of American Pathologists.

      In 2013, a registry study named OAR was initiated to follow long-term outcomes in allograft
      recipients receiving commercial AlloMap testing for surveillance (NCT01833195). The current
      objective is to enroll volunteers who are participating in the OAR registry(1) to
      co-participate in this observational sub-study, named D-OAR, in order to study a new
      biomarker, dd-cfDNA.

      dd-cfDNA has been proposed as a marker for cellular injury caused by rejection(2, 3). Because
      dd-cfDNA and the AlloMap test measure different signals in the blood, a combination of the
      two approaches could be additive since AlloMap is a measure of host immune response and
      dd-cfDNA monitors graft injury.

      The dd-cfDNA measurement is intended for the quantitative detection of plasma dd-cfDNA as a %
      of the total plasma cell-free DNA. Its utility as a surveillance tool in the management of
      heart transplant recipients is being investigated.

      This is an observational sub-study for subjects who are co-enrolled to participate in the
      Outcomes AlloMap Registry (OAR). Prior to implementation of the amendment dated September 15,
      2016, blood specimens were collected for assay of dd-cfDNA levels at each visit that occurred
      for AlloMap testing, per the OAR Study. As stated in the OAR study, the regular surveillance
      schedule for testing with AlloMap is determined by each participating center's standard of
      care. After this protocol amendment, the existing patients will no longer have routine
      dd-cfDNA specimens drawn to be paired with their standard of care AlloMap. The dd-cfDNA
      specimen will be drawn only when the patient is scheduled for a for-cause biopsy. New
      patients may be enrolled any time post-transplant as long as they have not had more than 1
      prior AlloMap. These patients will also only undergo routine AlloMap testing as per
      participating center's standard of care and dd-cfDNA specimen will be drawn when the patient
      is scheduled for a for-cause biopsy. An AlloMap sample will be drawn for research use along
      with the dd-cfDNA specimen at the time of the for-cause biopsy where the center's
      infrastructure permits. An additional two follow-up dd-cfDNA specimens will be collected in
      the patients that undergo a for-cause biopsy, and are being treated for rejection and/or
      graft dysfunction, as per their standard of care schedule. The two follow-up visits will not
      be paired with a research use AlloMap and will be performed within 8 weeks after the for
      cause event. If a patient returns for another for-cause biopsy, the center may opt to collect
      another research AlloMap and dd-cfDNA specimen, and two follow-up dd-cfDNA specimens.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Clinical Outcomes (Vital Status of Heart Transplant Recipients)</measure>
    <time_frame>3 years</time_frame>
    <description>Graft dysfunction, Rejection with hemodynamic compromise:
Hemodynamic compromise is defined by the presence of one or more of the following criteria:
Proportional decrease in LVEF ≥ 25%, Absolute LVEF ≤ 30%, Need for inotropic support, Cardiac index &lt; 2.0 L/min/m2, Death (re-transplantation)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cardiac Transplant Failure</condition>
  <condition>Cardiac Transplant Rejection</condition>
  <condition>Heart Diseases</condition>
  <arm_group>
    <arm_group_label>Heart Transplant Recipients</arm_group_label>
    <description>Heart allograft recipients undergoing scheduled surveillance visits that are part of a long-term management plan.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      donor derived cf-DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Heart allograft recipients undergoing scheduled surveillance visits that are part of a
        long-term management plan.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Any heart transplant recipient eligible for initiation and participation in the
             Outcomes AlloMap Registry (OAR) Study of regular AlloMap testing.

          2. Patients can be enrolled any time as long as they have not had more than 1 prior
             AlloMap.

          3. Written informed consent must be obtained prior to study enrollment. Exclusion
             Criteria

        1. Pregnant Women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James P Yee</last_name>
    <role>Study Director</role>
    <affiliation>CareDx Inc (formerly XDx Inc) Brisbane, CA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Preethi Prasad</last_name>
    <phone>415-287-2558</phone>
    <email>pprasad@CareDx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean Sana</last_name>
    </contact>
    <investigator>
      <last_name>Jon Kobashigawa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Luikart</last_name>
    </contact>
    <investigator>
      <last_name>Kiran Khush, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Regional Hospital</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Guedes</last_name>
    </contact>
    <investigator>
      <last_name>Ioana Dumitru, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Joughin</last_name>
    </contact>
    <investigator>
      <last_name>Peter Berman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginia Bowen</last_name>
    </contact>
    <investigator>
      <last_name>Robert Cole, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Rodgers</last_name>
    </contact>
    <investigator>
      <last_name>Jayant Raikhelkar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent Medical Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Wheeler</last_name>
    </contact>
    <investigator>
      <last_name>Ashwin Ravichandran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebekah Evans</last_name>
    </contact>
    <investigator>
      <last_name>Navin Rajagopalan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Davis</last_name>
    </contact>
    <investigator>
      <last_name>Selim Krim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neha Shah</last_name>
    </contact>
    <investigator>
      <last_name>Monica Colvin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Koukol</last_name>
    </contact>
    <investigator>
      <last_name>Emil Missov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mid America Heart Institute - St. Luke's Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline Smith</last_name>
    </contact>
    <investigator>
      <last_name>Andrew Kao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lizzy Ehrhard</last_name>
    </contact>
    <investigator>
      <last_name>Gregory Ewald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Donahey</last_name>
    </contact>
    <investigator>
      <last_name>Sean Pinney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Kim</last_name>
    </contact>
    <investigator>
      <last_name>Farhana Latif, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Gus</last_name>
    </contact>
    <investigator>
      <last_name>Randall Starling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie Kellum</last_name>
    </contact>
    <investigator>
      <last_name>Sitaramesh Emani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Integris Baptist Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Mayes</last_name>
    </contact>
    <investigator>
      <last_name>Janardhana Gorthi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Drexel University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Machen</last_name>
    </contact>
    <investigator>
      <last_name>Manreet Kanwar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Traci McGaha</last_name>
    </contact>
    <investigator>
      <last_name>Michael Shullo, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shane Blakenship</last_name>
    </contact>
    <investigator>
      <last_name>Shelley Hall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Kepinski</last_name>
    </contact>
    <investigator>
      <last_name>Pradeep Mammen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor St. Lukes</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melyssa Fink</last_name>
    </contact>
    <investigator>
      <last_name>Andrew Civitello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intermountain Heart Institute</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna French</last_name>
    </contact>
    <investigator>
      <last_name>Abdallah G Kfoury, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Johnson</last_name>
    </contact>
    <investigator>
      <last_name>Keyur Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora St. Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marilyn Miller</last_name>
    </contact>
    <investigator>
      <last_name>Nasir Sulemanjee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://allomap.com/</url>
    <description>Click her for more information about AlloMap testing</description>
  </link>
  <reference>
    <citation>Grskovic M, Hiller DJ, Eubank LA, Sninsky JJ, Christopherson C, Collins JP, Thompson K, Song M, Wang YS, Ross D, Nelles MJ, Yee JP, Wilber JC, Crespo-Leiro MG, Scott SL, Woodward RN. Validation of a Clinical-Grade Assay to Measure Donor-Derived Cell-Free DNA in Solid Organ Transplant Recipients. J Mol Diagn. 2016 Nov;18(6):890-902. doi: 10.1016/j.jmoldx.2016.07.003. Epub 2016 Oct 7.</citation>
    <PMID>27727019</PMID>
  </reference>
  <results_reference>
    <citation>Kobashigawa, JA. et al; Initial Analysis of the Donor-Derived Cell-Free DNA -Outcomes AlloMap Registry (D-OAR) Study in Heart Transplant Recipients Undergoing Surveillance for Rejection. 2016 ISHLT 36th Annual Meeting and Scientific Sessions. April 27-30, 2016; Washington, DC</citation>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2014</study_first_submitted>
  <study_first_submitted_qc>June 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2014</study_first_posted>
  <last_update_submitted>August 10, 2017</last_update_submitted>
  <last_update_submitted_qc>August 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Molecular Diagnostics</keyword>
  <keyword>Heart Transplantation</keyword>
  <keyword>Risk Factors</keyword>
  <keyword>Prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

